马丁·什克雷利（Martin Shkreli）爆炸了FDA生物制度评估与研究中心（CBER）的新负责人Vinay Prasad，作为“坚果”

这不是投资建议。作者在提到的任何股票中都没有立场。 WCCFTECH.com有披露和道德政策。

Martin Shkreli, the former hedge fund manager who was once dubbed the most hated C-suite executive in America for massively hiking the price of a life-saving drug, is known for his proclivity to comment on all things pharma-related.

马丁·什克雷利（Martin Shkreli）是前对冲基金经理，他曾被称为美国最讨厌的C-Suite高管，因为他大量远足了挽救生命的药物的价格，他以对与药物有关的所有事物发表评论而闻名。

In keeping with this, Shkreli has just landed a few hard-hitting punches against the new head of FDA’s Center for Biologics Evaluation and Research (CBER), Vinay Prasad.

为此，Shkreli刚刚对FDA生物学评估与研究中心（CBER）的新负责人（Vinay Prasad）进行了一些艰苦的拳头。

The only "emergency" America still faces with covid-19 is that regulators like Peter Marks are either incompetent or corrupt to authorize a booster without clinical, randomized data.https://t.co/EByJciOSGI

美国唯一与Covid-19的“紧急情况”是，彼得·马克（Peter Marks）这样的监管机构是无能或腐败的，可以授权助推器，而没有临床，随机数据。https：//t.co/ebyjciosgi

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 22, 2024

-Vinay Prasad MD MPH（@vprasadmdph）2024年8月22日

For the benefit of those who might not be aware, Prasad is an oncologist who has made a name for himself by vehemently opposing COVID-19 booster shots.

为了那些可能不知道的人的好处，普拉萨德是一位肿瘤学家，他通过强烈反对的Covid-19助推器射击为自己而闻名。

In a recent blog post, Prasad diligently argued in favor of additional randomized trials for COVID-19 booster shots before updating the current inoculation recommendations.

在最近的博客文章中，普拉萨德（Prasad）勤奋地争辩说，在更新当前的接种建议之前，支持了COVID-19-19的其他随机试验。

I have talked to the heads of almost ever single one of big pharma in the last 72 hours and he has no idea what is like out there. NONE! And Prasad has NO IDEA what it’s like out there. My people have been in this game for 25 years and they’re LOSING THEIR JOBS and these firms…

在过去的72个小时中，我已经与几乎一个大型制药公司的单身人士交谈，他不知道那里是什么样的。没有任何！ Prasad不知道那里的情况。我的人民从事这个游戏已有25年了，他们正在失去工作和这些公司……

— Martin Shkreli (@MartinShkreli) May 5, 2025

- Martin Shkreli（@martinshkreli）2025年5月5日

This brings us to the crux of the matter. Martin Shkreli has now jumped into the growing controversy around Prasad’s appointment by asserting that the new head of the CBER is “nuts,” and has “no idea” about the ground realities of the nation’s pharma landscape.

这使我们进入了问题的症结。马丁·什克雷利（Martin Shkreli）现在涉及普拉萨德（Prasad）任命的越来越多的争议，称新的CBER负责人是“坚果”，并且对美国制药景观的基础现实“不知道”。

Martin Shkreli asserts that he has been in touch with the “heads of almost ever[y] single one of big pharma in the last 72 hours,” and that these firms are “gonna go out of business.”

马丁·什克雷利（Martin Shkreli）断言，他一直与“过去72小时的大型制药公司（Big Pharma）几乎拥有过的单身人士”与他们保持联系，并且这些公司“会倒闭”。

Basically, Martin Shkreli thinks that Vinay Prasad will institute a more meticulous testing and trial regime at the CBER, which would strangle many of the pharma firms already contending with an increasingly competitive landscape and escalating job losses.

基本上，马丁·什克雷利（Martin Shkreli）认为，Vinay Prasad将在CBER进行更细致的测试和试验制度，这将扼杀许多已经与竞争日益激烈的景观竞争并升级工作损失的制药公司。

As an illustration of this evolving paradigm, consider the fact that Bristol Myers Squibb (BMS) announced the layoff of 516 employees in April 2025, bringing its total layoffs so far this year to 806. Do note that BMS also shed 2,200 jobs in 2024.

为了说明这一不断发展的范式，考虑到布里斯托尔·迈尔斯·索斯（Bristol Myers Squibb）（BMS）在2025年4月宣布了516名员工的裁员，今年到目前为止，其总裁员达到806。

Of course, some would view Martin Shkreli’s criticism of Vinay Prasad as a badge of honor of sorts - an indication that the new head of the CBER is not beholden to corporate interests. Yet, others might interpret this volley as an SOS for a besieged industry.

当然，有些人会将马丁·什克雷利（Martin Shkreli）对Vinay Prasad的批评视为一种荣誉的徽章，这表明CBER的新负责人并不注视着公司利益。但是，其他人可能将这个凌空作解释为被包围行业的SOS。

Do you agree with Martin Shkreli’s criticism of Vinay Prasad? Is it not the very ethos of capitalism that the fittest firms should survive and struggling ones perish? Let us know your thoughts in the comments section below.

您是否同意马丁·什克雷利（Martin Shkreli）对Vinay Prasad的批评？最优胜心的企业应该生存并挣扎的人灭亡，这不是资本主义的精神吗？在下面的评论部分中让我们知道您的想法。